Clinical trials: Apatinib
Sarcoma
MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma
This study will evaluate the safety and preliminary efficacy of Multi-Antigen Stimulated Cell Therapy-I Injection (MASCT-I) in combination with Apatinib and/or Camrelizumab in patients with advanced bone and soft-tissue sarcoma.
- Trial name
- NCT04074564
- Testing
- MASCT-I, Camrelizumab,Apatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- HRYZ Biotech Co.
Sarcoma
A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma
The main purpose of this study is to evaluate the efficacy of SHR-1210 plus Apatinib versus AMD plus IFO in participants with soft tissue sarcoma.
- Trial name
- NCT03711279
- Testing
- SHR-1210 plus Apatinib, ADM plus IFO or IFO alone
- Where
- China
- Volunteers
- 99 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.